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HIV-1  diversity  has  been  considered  a huge  challenge  for the  HIV-1  vaccine  development.  To  overcome  it,
immunogens  based  on  centralized  sequences,  as consensus,  have  been  tested.  In Brazil,  the co-circulation
of  three  subtypes  offers  a  suitable  scenario  to  test  T cell  cross-subtype  responses  to  consensus  sequences.
Furthermore,  we  included  peptides  based  on  closest  viral  isolates  (CVI)  from  each  subtype  analyzed  to
compare  with  T cell  responses  detected  against  the  consensus  sequences.  The  study  included  32  subjects
infected  with  HIV-1  subtype  B  (n = 13),C  (n =  11),  and  F1  (n = 8).  Gag  and  Nef-speciﬁc  T cell responses
were  evaluated  by  IFN--ELISpot  assay.  Peptides  based  on  CVI  sequences  were  similar  to consensus  in
both reducing  genetic  distance  and  detecting  T cell  responses.  A  high  cross-subtype  response  between
B  and  F1  in both  regions  was observed  in  HIV-1  subtype  B and  F1-infected  subjects.  We  also  found  no
signiﬁcant  difference  in responses  to subtype  B  and  C  consensus  peptides  among  subtype  B-infected
subjects.  In  contrast,  the  magnitude  of  T  cell  responses  to  consensus  C  peptides  in  the  Gag  region  was
higher  than  to  consensus  B  peptides  among  HIV-1  subtype  C-infected  subjects.  Regarding  Nef, subtype  C-
infected  subjects  showed  higher  values  to consensus  C  than  to consensus  F1  peptides.  Moreover,  subtype
F1-infected  subjects  presented  lower  responses  to  subtype  C peptides  than  to subtype  F1  and  B. A similar
level  of responses  was  detected  with  group  M  based  peptides  in  subtype  B and  F1 infected  subjects.
However,  among  subtype  C infected  subjects,  this  set  of  peptides  detected  lower  levels  of  response  than
consensus  C.  Overall,  the  level  of cross-subtype  response  between  subtypes  B  and  F1 was  higher  than
between  subtype  C  and  B  or  C  and  F1.  Our  data  suggests  that  the  barrier  of  genetic  diversity  in  HIV-1
group  M  for  vaccine  design  may  be dependent  on  the  subtypes  involved.. Introduction
The development of safe and effective HIV vaccines offers the
est hope for the prevention of new infections. However, HIV-1
accine efforts have not yet proven successful [1].  Among the four
accine efﬁcacy trials in human volunteers, only the recent RV144,
onducted in Thailand, showed statistically signiﬁcant rate of pro-
ection, despite the fact that vaccine efﬁcacy was 31.2% [2].
The high mutation rate of HIV-1 allows the virus to rapidly
vade immune responses [3].  In fact, the genetic variability of
∗ Corresponding author at: Laboratório de Aids e Imunologia Molecular, Insti-
uto Oswaldo Cruz, Fundac¸ ão Oswaldo Cruz, Avenida Brasil, 4365, Rio de Janeiro, RJ
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E-mail address: mmorgado@ioc.ﬁocruz.br (M.G. Morgado).
264-410X     ©  2012 Elsevier Ltd. 
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HIV-1 is considered one of the major challenges for the design of
effective vaccines that could protect from heterologous viral infec-
tion [4] and for the development of reagents to evaluate vaccine
immunogenicity. Even within the same HIV-1 subtype the amino
acid sequence can diverge by >15%, whereas genetic distances
between isolates of distinct subtypes can exceed 30% depending
on the genomic region analyzed [5].
In areas where different HIV-1 subtypes co-circulate, this diver-
sity is reﬂected in the emergence of unique recombinant forms
and CRFs. In Brazil, the subtype B is prevalent in most geographic
regions, followed by BF1 recombinants, and subtype F1 [6–9].
This scenario is different in the Southern Brazilian region, where
Open access under the Elsevier OA license.subtype C and BC recombinants are highly prevalent [10]. The co-
circulation of subtype B and BF1 recombinants is also found in other
South American countries, such as Argentina, Chile, Uruguay and
Paraguay [11–13].
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A globally effective vaccine should protect against a variety of
IV-1 genetic forms. To overcome this diversity, several strate-
ies of immunogen design have been proposed, as inclusion of
istinct HIV subtype target antigens [2] engineered antigens, such
s polyvalent mosaic [14] and centralized [15–18] sequences. The
oal of these strategies is to reduce the amino acid sequence
istance between immunogens and circulating viruses. Since
IV-1 phylogeny present a star-like conﬁguration, the use of a
central sequence” should diminish the amino acid difference
etween immunogens and circulating virus [16]. Among central-
zed sequences, consensus sequences have been commonly used
o evaluate immune responses in HIV-1-infected subjects [19–22].
accines based on consensus sequences stimulated cross-subtype
esponses in animal models [23–25],  and cross-reactivity was
etected using peptides based on the consensus of target regions
n cohorts from different ethnicities infected with diverse subtypes
26–28].
Evaluation of cross-reactivity responses among HIV-1 subtypes
revalent in South America are scarce, and the high miscegenation
f the Brazilian population offers a heterogeneous HLA background
o study T cell responses in HIV-1 infected subjects [29]. The objec-
ive of this study was to evaluate the potential usage of consensus
equences for the deﬁnition of viral immunogens, and to analyze
he cross-subtype responses in a cohort of HIV-1 subtype B-, C-, and
1-infected Brazilian subjects. An additional strategy of immuno-
en design, here called closest viral isolate (CVI), which was based
n the identiﬁcation of the circulating virus with the lowest genetic
istance to the consensus in a given population, was also evaluated
n this study.
. Materials and methods
.1. Study population
The study included 32 Brazilian subjects infected with HIV-1
ubtypes B (n = 13), C (n = 11), and F1 (n = 8), followed at Hospi-
al Evandro Chagas (Rio de Janeiro, RJ), Hospital Geral de Nova
guac¸ u (Nova Iguac¸ u, RJ), and Hospital Homero de Miranda Gomes
São José, SC). All subjects have detectable viral load and lympho-
ytes TCD4+ counts > 200 cells/L. The study was  approved by the
espective Institutional Review Committees and all participants
ave written informed consent.
.2. Cells
Blood was collected by sterile venipuncture, and samples were
rocessed on the day of collection. Peripheral blood mononuclear
ells (PBMC) were isolated by density gradient centrifugation using
istopaque 1077 (Sigma–Aldrich, USA), and cryopreserved in 90%
etal bovine serum (FBS-Gibco, Invitrogen, USA), and 10% dimethyl
ulfoxide (Sigma–Aldrich, USA).
.3. Lymphocytes T CD4+ counts and viral load
Absolute TCD4+ cells counts were measured using the MultiTest
ruCount-kit and the MultiSet software on a FACSCalibur (BD Bio-
ciences, USA). Plasma HIV-1 viral loads were measured using the
ersant HIV-1 3.0 RNA assay (bDNA, Siemens Healthcare Diagnos-
ics, USA).
.4. Extraction, PCR ampliﬁcation, and sequencing of HIV-1 DNADNA samples were extracted from whole blood using QIAamp
iral DNA Kit (QIAgen Inc., USA), according to the manufacture’s
rotocol, and PCR-ampliﬁed using nested primers. Ampliﬁcation
f gag region was performed using SCAOSD [30] and G17 [31] as1 (2013) 1106– 1112 1107
outer primers, and SCANSD [30] and p24-1 [32] as inner primers.
Ampliﬁcation of the nef fragment was carried out using NEF-1 [33]
and SCDOAD [30] as outer primers, and NEF-3 [34] and SCDNAD
[30] as inner primers. PCR conditions were performed as described
elsewhere [6].
PCR products were puriﬁed with Illustra GFX PCR DNA Kit (GE
Healthcare, USA), and sequenced using the Big Dye Terminator v3.1
Kit (Applied Biosystem, USA). Sequencing reactions were analyzed
with an ABI 3100 automated sequencer. Sequences were edited
with Seqman v7.0 program (DNASTAR; Lasergene, USA).
2.5. Consensus and closest viral isolate (CVI) sequences
A total of 220 Brazilian sequences were retrieved from the
Los Alamos HIV database (http://www.hiv.lanl.gov), and from
the sequence database from our laboratory (subtype B [gag = 21,
nef = 51], subtype C [gag = 34, nef = 45], and subtype F1 [gag = 31,
nef = 38]). They were used to infer the subtype B, C, and F1 Brazilian
consensus sequences of gag and nef regions employing the software
Dambe v.5.0.10. Group M-consensus sequence was retrieved from
the Los Alamos HIV database. The subtype B, C, and F1 Brazilian
sequences, with the lowest genetic distance to the correspond-
ing subtype consensus in both gag and nef regions, were deﬁned
as the closest viral isolates (CVI). Nucleotide distance between
sequences and subtype consensus sequences were calculated using
the Tamura–Nei model as implemented in MEGA  v40 [35]. Amino
acid sequences were obtained by translating consensus and CVI
nucleotide sequences.
2.6. Synthetic peptides
Sets of peptides (15-mers with 11-aa overlaps) based on the
Brazilian consensus and CVI subtype B, C, and F1 covering Gag
(amino acids 17–43, and 64–103 related to the HXB2 Gag protein),
and Nef (amino acids 68–160 related to the HXB2 Nef protein) frag-
ments were produced by polypeptide (USA). These regions were
chosen based on a previous study from our group [36], that showed
high frequencies of responses to these positions in Gag p17 and
the Nef central region. Overlapping peptides were divided into two
pools for Gag p17 and four pools for Nef, according to the position
in protein. The ﬁnal concentration of each peptide within a peptide
pool was  4 g/mL.
2.7. IFN- ELISpot
The ELISPOT IFN- assay was  performed as described previ-
ously [37]. Brieﬂy, 96-well plates (Millipore, USA) were coated with
anti-human IFN- mAb  (Diaclone, France). HIV-1 peptide pools
were diluted in complete culture medium [RPMI 1640 (Sigma,
USA) supplemented with 10% of FBS, Penicillin–Streptomycin
(10,000 U–10,000 g/mL), l-glutamine 200 mM,  non-essential
amino acids 10 mM,  and sodium pyruvate 100 mM  (all purchased
from invitrogen, USA)]. PBMCs were added at an input cell number
of 1 × 105 cells/well. Phytohemagglutinin-5 g/ml (Sigma, USA)
was  used as a positive control, and cells suspended only in cul-
ture medium served as a negative control. The spots were counted
using an automated ELISPOT reader (CTL Analyzers LLC, Cellu-
lar Technology, USA). The results were expressed as spot-forming
cells (SFC)/million PBMCs. The response was considered positive if
≥50 SFC/106 PBMCs were detected.
2.8. Statistical analysisStatistical analyses were performed using GraphPad 5.0 (Prism
Software, USA). The Wilcoxon test was used to compare genetic
distance between infecting viral sequences and consensus or CVI
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Table  1
Summary of viral load and CD4+ T cell counts according to the HIV-1 subtype infection.
Laboratory data,
median (IQRs)
HIV-1 subtypes (number of participants)
Subtype B (13) Subtype C (11) Subtype F1 (8) Overall (32)
Plasma HIV RNA level,
copies/mL*
3,483
(375–12,521)
12,663
(920–16,200)
12,915
(3,738–32,396)
8,543
(911–15,711)
CD4+ T cell count 736 519
)
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scells/L* (565–1,014) (431–654
* No signiﬁcantly differences were observed among the CD4+ T cell count and vir
equences, and the magnitude of responses against consensus and
VI peptides. The Friedman test was performed to compare genetic
istances and the magnitude of HIV-1 cross-subtype responses,
ollowed by a Dunn’s post-test for multiple comparisons. Corre-
ations were determined using Spearman’s rank test. All tests were
onsidered signiﬁcant if the p value was below 0.05.
. Results
.1. Study population
The summary of laboratory data for subjects included in this
tudy, distributed according to the subtype of the HIV-1-infecting
irus, is presented in Table 1. Overall, the median of absolute lym-
hocyte T CD4+ cell count was 617 cells/L (IQR = 485–790), and
he median of plasma RNA viral load (VL) was 8,543 copies/mL
IQR = 911–15,711). No statistically signiﬁcant differences were
ound for VL and CD4T cell counts among the groups.
.2. Genetic distance to consensus and CVI of HIV-1 subtypes B, C,
nd F1
The mean genetic distances between the Brazilian sequences,
sed to derive consensus, and the corresponding subtype consen-
us for gag and nef regions were: 3.9% and 5.3% for subtype B; 3.0%
nd 3.2% for subtype F1; and 3.7% and 4.1% for subtype C, respec-
ively. The genetic distances between the CVI sequences and the
orresponding subtype set of sequences were: 5.8% (gag) and 6.8%
nef) for subtype B; 4.9% (gag) and 5.2% (nef) for subtype F1; and 5.8%
gag) and 4.2% (nef) for subtype C. Phylogenetic trees of gag and nef
enes showing the positions of both consensus and CVI sequences
re presented in Supplemental File (Fig. S1).
Next, we determined the mean genetic distance between con-
ensus and CVI overlapping peptide sequences for each target used
or the ELISpot IFN- assays and the viral amino acid sequence of
ach study subject. The mean genetic distances to consensus and
VI were similar for all subtypes on both regions analyzed, with
xception of subtype B infected subjects that displayed signiﬁcantly
p = 0.0015) lower mean genetic distance to consensus (8.6%) than
o CVI (13.8%) in the Gag region (Fig. 1A and B). These results suggest
hat the capacity of both consensus and CVI sequences to minimize
he genetic distance to Brazilian circulating viruses was roughly
imilar, although they might vary according to the genetic region
nd subtype considered.
.3. Immune response to consensus and CVI of HIV-1 subtypes B,
, and F1
To compare the capacity of peptide pools corresponding to CVI
nd consensus sequences of HIV-1 subtypes B, C, and F1 to elicit T
ell responses, the median of the magnitude of responses was calcu-
ated based on the sum of the number of IFN--secreting cells/106
BMCs for each Gag or Nef peptide set. Consensus and CVI peptides
howed similar median of magnitude of responses, independently(353–842) (485–790)
. All p values > 0.05.
of subtype evaluated (Fig. 1C and D) for both regions. The
overall magnitude of response to Nef was  higher than to Gag
peptide pools. It is important to indicate that F1 subtype-infected
subjects showed higher responses to Gag peptides than those
infected with subtypes B or C.
3.4. Cross-reactivity responses among subtype B, C, F1 and group
M
Intra and inter pairwise distances were calculated based on the
amino acid sequence of each sample against consensus peptides
used as ELISpot reagent (Fig. 2A and B). The mean intra-subtype
genetic distances were signiﬁcantly lower than the mean inter-
subtype, except for the subtype F1-infected patients that displayed
a mean genetic distance to consensus F1 (8%) similar to consensus B
(7.2%) in Nef region. Mean genetic distances to M consensus ranged
from 14 to 24% for Gag and 10–13% for Nef.
The degree of cross-reactivity to each subtype consensus and
group M peptides was evaluated in Gag and Nef. Positive response
to at least one consensus peptide set was  detected for 93% of the
patients. In contrast with what was  observed in genetic distances,
the mean magnitude of responses, expressed as SFC/106 PBMCs, in
subtype B-infected individuals, showed no signiﬁcantly differences
against the four peptides sets tested in both Gag and Nef. In subtype
C-infected subjects, the mean magnitude of responses to consensus
C (Gag = 190; Nef = 628) were signiﬁcantly higher than to consen-
sus B (Gag = 24; Nef = 463), consensus M (Gag = 35; Nef = 421), and
consensus F1 (Nef = 368). In subtype F1-infected subjects, similar
to observed in subtype B-infected subjects, a high cross-reactivity
was  demonstrated to consensus B and M.  However, the magnitude
of responses to consensus C, in Gag, was  signiﬁcantly lower (Fig. 2C
and D).
3.5. Correlation between genetic distance and magnitude of T cell
responses to Gag and Nef peptides
The genetic distance between the viral infecting sequences
from the three groups and consensus B, C, F1, and group M pep-
tides had a signiﬁcant impact on the anti-Gag T cell responses,
demonstrated by a negative correlation (Spearman’s r = −0.2227;
p = 0.0145) (Fig. 3A), while no signiﬁcant correlation was  observed
for Nef (Fig. 3B).
4. Discussion
The genetic diversity of HIV-1 is considered one of the major
challenges for the design of effective vaccines. One of the most pop-
ular strategies of immunogen design proposed to overcome this
problem is the use of centralized sequences, such as consensus,
that are also frequently used to derive reagents to assess immune
responses in HIV-infected subjects. In the present study, we com-
pared the capacity of consensus sequences, and primary isolate
sequences that most closely resemble consensus (CVI), to both
reduce the genetic distance and maximize the immune response
F.H. Côrtes et al. / Vaccine 31 (2013) 1106– 1112 1109
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Fig. 1. Comparison between consensus and CVI peptides. Amino acid distances between infecting viral sequences and peptides derived from consensus and CVI sequences
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gainst the three prevalent HIV-1 subtypes circulating in Brazil: B,
, and F1.
Previous studies demonstrated a high similarity between con-
ensus and isolate sequences most similar to consensus (>80%
n Gag and >70% in Nef), and also a high percentage of positive
esponses in IFN- ELISpot assays against peptides derived from
solate sequences [38–40].  However, no comparison has been per-
ormed between consensus and isolate sequences in context of T
ell immune response. Here we demonstrate that the CVI sequence
s similarly powerful for both reducing the genetic distance to circu-
ating viruses, and for the detection of HIV-speciﬁc T cell responses
o Gag and Nef when compared to consensus for all three subtypes
nalyzed.
For vaccine design, it is of paramount importance the iden-
iﬁcation of cross-reactive HIV antigens to cover the high HIV
iversity. Several studies indicate that Gag and Nef highly con-
erved epitope regions are commonly recognized, and give rise to
igh inter-subtype cross-reactive T-cell responses [26,28,41–43];
lthough the overall frequency and magnitude of inter-subtype
-cell responses is typically lower than that of the intra-subtype
26,28,44]. We  found a high cross-subtype response between
ubtype B and F1 for both Gag and Nef regions, compara-
le to the frequency and/or magnitude of intra-subtype T-cell
esponses. This data is in agreement with a previous study that
lso described a high T-cell cross-reactivity between subtypes B
nd F1 among HIV positive individuals from Argentina using Nef
eptides [45]. High cross-reactivity between subtypes B and F1
ave also been observed for neutralizing antibodies [46]. These
esults open a good perspective for vaccine design for coun-
ries where these two  subtypes are predominating, as in South
merica.IV-1 subtype B-, C-, and F1-infected subjects, stimulated with Gag (C) or Nef (D)
s ≥ 50 SFC/106 PBMCs were considered positive. P values were calculated using the
No signiﬁcant difference in the magnitude of the responses
to subtype B and C Gag and Nef consensus peptides was found
among subtype B-infected subjects, consistent with other studies
demonstrating a similar magnitude or breadth of T cell responses
to subtype B and C peptides in populations infected mainly with
subtype B [38,43].  In contrast, the magnitude of T cell responses to
consensus C peptides in the Gag region was signiﬁcantly higher
than to consensus B peptides among HIV-1 subtype C-infected
subjects. Previous studies with subtype C-infected subjects also
demonstrated a lower magnitude of response to subtype B con-
sensus when compared with intra-subtype responses [26,28].
Signiﬁcant differences in the level of cross-subtype responses
were also observed between subtype C and F1. Among subtype C-
infected subjects, the median magnitude of responses to consensus
C was  higher than to consensus F1 peptides in Nef, whereas among
subtype F1-infected subjects the median magnitude of responses
to consensus F1 peptides in Gag was  higher than to consensus C
peptides.
Consensus group M based immunogens have been proposed as
an alternative to vaccine design in regions where different subtypes
co-circulate [27,47]. Peptide pools based on group M consensus
sequences detected responses of similar breadth and magnitude
as did consensus B or consensus C peptides in subtype B- and C-
infected patients, respectively [27]. Gag and Nef peptides derived
from HIV-1 consensus group M also detected responses in subtype
A1 and D infected subjects [47] demonstrating that this strategy
is useful for different subtypes. Our results conﬁrm that group M
consensus peptides were as efﬁcient as subtype-speciﬁc consen-
sus peptides for subtype B- and F1-infected subjects, but not for
subtype C-infected patients. Among subtype C-infected patients,
group M consensus peptides elicited a signiﬁcant lower magnitude
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Fig. 2. Evaluation of cross-reactivity. Amino acid distances between infecting viral sequences and peptides derived from subtype B, C, F1, and group M consensus sequences
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f response than subtype C consensus peptides. This difference in
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The extensive genetic diversity of the HIV-1 group M isolates and
ts implications for vaccine design have long been debated. While
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in Gag, but no correlation was  demonstrated in Nef. Although the
genetic distances to the homologous consensus peptides in Nef
were signiﬁcantly lower than to heterologous consensus ones, the
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agnitude of intra-subtype and inter-subtype responses was  quite
omogenous for most comparisons in this region. Finally, although
he mean genetic distance among prevalent Brazilian subtypes
as roughly similar, we observed that the level of cross-subtype
esponse between subtypes B and F1 was higher than between
ubtype C and B or between subtype C and F1. These data demon-
trate that associations between T cell responses and phylogenetic
roximity are complex.
Our data demonstrate that peptide pools based on natural CVI
trains are able to minimize the genetic distance to circulating
iruses and to detect responses of similar breadth and magnitude
s peptides based on artiﬁcial consensus sequences. They also indi-
ate that the signiﬁcance of the HIV-1 group M genetic diversity
or vaccine design may  be dependent of the subtypes involved and
he genomic region considered. We  also point out that the nega-
ive impact of genetic distance on T cell recognition could be more
mportant for Gag than Nef. Overall, these results emphasize that it
s probably necessary to use a multi-subtype immunogen to match
he predominant HIV-1 subtypes that circulate in the Brazilian pop-
lation, especially if peptides based on Gag are included in the
accine formulation.
cknowledgements
This work was supported by Department of STD, AIDS and Viral
epatitis/Brazilian Ministry of Health. Fernanda Heloise Côrtes is
ecipient of a CNPq Fellowship. We  thank all the patients that par-
icipated in this study, the Program for Technological Development
n Tools for Health-PDTIS/FIOCRUZ for use of its facilities and Vera
ongertz for critical reviewing of the manuscript.
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.vaccine.2012.12.023.
eferences
[1] Girard MP,  Osmanov S, Assossou OM,  Kieny MP.  Human immunodeﬁciency
virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine
2011;29(37):6191–218.
[2] Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris
R,  et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N Engl J Med  2009;361(23):2209–20.
[3] Boutwell CL, Rolland MM,  Herbeck JT, Mullins JI, Allen TM.  Viral evolution
and  escape during acute HIV-1 infection. J Infect Dis 2010;202(October (Suppl
2)):S309–14.
[4] Garber DA, Silvestri G, Feinberg MB.  Prospects for an AIDS vaccine: three big
questions, no easy answers. Lancet Infect Dis 2004;4(7):397–413.
[5] Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolution-
ary  and immunological implications of contemporary HIV-1 variation. Br Med
Bull  2001;58:19–42.
[6] Morgado MG,  Guimaraes ML,  Gripp CB, Costa CI, Neves Jr I, Veloso VG, et al.
Molecular epidemiology of HIV-1 in Brazil: high prevalence of HIV-1 subtype B
and identiﬁcation of an HIV-1 subtype D infection in the city of Rio de Janeiro,
Brazil. Evandro Chagas Hospital AIDS Clinical Research Group. J Acquir Immune
Deﬁc Syndr Hum Retrovirol 1998;18(August (5)):488–94.
[7] Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, et al. Drug-
resistant reverse transcriptase genotyping and phenotyping of B and non-B
subtypes (F and A) of human immunodeﬁciency virus type I found in Brazilian
patients failing HAART. Virology 2000;275(September (1)):107–15.
[8] Machado LF, Ishak MO,  Vallinoto AC, Lemos JA, Azevedo VN, Moreira MR, et al.
Molecular epidemiology of HIV type 1 in northern Brazil: identiﬁcation of sub-
types C and D and the introduction of CRF02 AG in the Amazon region of Brazil.
AIDS Res Hum Retroviruses 2009;25(October (10)):961–6.
[9]  Ferreira AS, Cardoso LP, Stefani MM.  Moderate prevalence of transmitted drug
resistance and high HIV-1 genetic diversity in patients from Mato Grosso State,
Central Western Brazil. J Med  Virol 2011;83(August (8)):1301–7.
10] Gräf T, Passaes CP, Ferreira LG, Grisard EC, Morgado MG, Bello G, et al. HIV-
1  genetic diversity and drug resistance among treatment naïve patients from
Southern Brazil: an association of HIV-1 subtypes with exposure categories. J
Clin Virol 2011;51(July (3)):186–91.
[1 (2013) 1106– 1112 1111
11] Montano SM,  Sanchez JL, Laguna-Torres A, Cuchi P, Avila MM,  Weissenbacher
M,  et al. Prevalences, genotypes, and risk factors for HIV transmission in South
America. J Acquir Immune Deﬁc Syndr 2005;40(September (1)):57–64.
12]  Gomez-Carrillo M,  Pampuro S, Duran A, Losso M,  Harris DR, Read JS, et al. Anal-
ysis of HIV type 1 diversity in pregnant women from four Latin American and
Caribbean countries. AIDS Res Hum Retroviruses 2006;22(11):1186–91.
13] Aguayo N, Laguna-Torres VA, Villafane M, Barboza A, Sosa L, Chauca G,  et al.
Epidemiological and molecular characteristics of HIV-1 infection among female
commercial sex workers, men  who  have sex with men  and people living with
AIDS in Paraguay. Rev Soc Bras Med  Trop 2008;41(May–June (3)):225–31.
14]  Fischer W,  Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al.
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global
HIV-1 variants. Nat Med  2007;13(1):100–6.
15] Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity consider-
ations in HIV-1 vaccine selection. Science 2002;296(5577):2354–60.
16] Nickle DC, Jensen MA,  Gottlieb GS, Shriner D, Learn GH,  Rodrigo AG,
et  al. Consensus and ancestral state HIV vaccines. Science 2003;299(March
(5612)):1515–7.
17] Gao F, Korber BT, Weaver E, Liao HX, Hahn BH, Haynes BF. Centralized immuno-
gens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines
2004;3(August (Suppl. 4)):S161–8.
18] Kesturu GS, Colleton BA, Liu Y, Heath L, Shaikh OS, Rinaldo CR, et al. Minimi-
zation of genetic distances by the consensus, ancestral, and center-of-tree (COT)
sequences for HIV-1 variants within an infected individual and the design of
reagents to test immune reactivity. Virology 2006;348(May (2)):437–48.
19] Frahm N, Korber BT, Adams CM,  Szinger JJ, Draenert R, Addo MM,  et al. Consis-
tent cytotoxic-T-lymphocyte targeting of immunodominant regions in human
immunodeﬁciency virus across multiple ethnicities. J Virol 2004;78(March
(5)):2187–200.
20] Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma  B, et al. Antigenicity and immunogenic-
ity  of a synthetic human immunodeﬁciency virus Type 1 group M consensus
envelope glycoprotein. J Virol 2005;79(2):1154–63.
21] Santra S, Korber BT, Muldoon M,  Barouch DH, Nabel GJ, Gao F, et al. A centralized
gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses
in  rhesus monkeys. Proc Natl Acad Sci USA 2008;105(30):10489–94.
22] Serwanga J, Mugaba S, Pimego E, Nanteza B, Lyagoba F, Nakubulwa S, et al.
Proﬁle of T cell recognition of HIV Type 1 consensus group M Gag and Nef
peptides in a clade A1- and D-infected Ugandan population. AIDS Res Hum
Retroviruses 2012;28(4):384–92.
23] Kothe DL, Li YY, Decker JM,  Bibollet-Ruche F, Zammit KP, Salazar MG,  et al.
Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology
2006;352(September (2)):438–49.
24] Santra S, Korber BT, Muldoon M,  Barouch DH, Nabel GJ, Gao F, et al. A centralized
gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses
in  rhesus monkeys. Proc Natl Acad Sci USA 2008;105(July (30)):10489–94.
25] Yan J, Corbitt N, Pankhong P, Shin T, Khan A, Sardesai NY, et al. Immunogenicity
of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA
vaccine. Vaccine 2011;29(September (41)):7173–81.
26] Frahm N, Nickle DC, Linde CH, Roach T, Walker BD, Allen TM,  et al. Increased
detection of HIV-speciﬁc T cell responses by combination of central sequences
with comparable immunogenicity. AIDS 2008;22(February (4)):447–56.
27] Bansal A, Gough E, Ritter D, Wilson C, Mulenga J, Allen S, et al. Group M-based
HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US
and Zambian patients. AIDS 2006;20(February (3)):353–60.
28] Zembe L, Burgers WA,  Jaspan HB, Bekker LG, Bredell H, Stevens G, et al. Intra-
and inter-clade cross-reactivity by HIV-1 Gag speciﬁc T-cells reveals exclusive
and commonly targeted regions: implications for current vaccine trials. PLoS
One 2011;6(10):e26096.
29] Williams F, Meenagh A, Darke C, Acosta A, Daar AS, Gorodezky C, et al. Analysis
of  the distribution of HLA-B alleles in populations from ﬁve continents. Hum
Immunol 2001;62(June (6)):645–50.
30] Sierra M, Thomson M,  Ríos M,  Casado G, Castro R, Delgado E, et al. The anal-
ysis of near full-length genome sequences of human immunodeﬁciency virus
type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain
reveals their relationship to diverse lineages of recombinant viruses related to
CRF12 BF. Infect Genet Evol 2005;5(April (3)):209–17.
31] Heyndrickx L, Janssens W,  Zekeng L, Musonda R, Anagonou S, Van der Auwera
G,  et al. Simpliﬁed strategy for detection of recombinant human immuno-
deﬁciency virus type 1 group M isolates by gag/env heteroduplex mobility
assay. Study group on heterogeneity of HIV epidemics in African cities. J Virol
2000;74(January (1)):363–70.
32] Lee CN, Chen MY,  Lin HS, Lee MC,  Luo CC, Twu SJ, et al. HIV type 1 env subtype
A  variants in Taiwan. AIDS Res Hum Retroviruses 1998;14(June (9)):807–9.
33] Artenstein A, Hegerich P, Beyrer C, Rungruengthanakit K, Michael N, Natpratan
C.  Sequences and phylogenetic analysis of the nef gene from Thai subjects har-
boring subtype E HIV-1. AIDS Res Hum Retroviruses 1996;12(April (6)):557–60.
34] Salvi R, Garbuglia AR, Di Caro A, Pulciani S, Montella F, Benedetto A. Grossly
defective Nef gene sequences in a human immunodeﬁciency virus type 1-
seropositive long-term nonprogressor. J Virol 1998;72(May (5)):3646–57.
35] Tamura K, Dudley J, Nei M,  Kumar S. MEGA4. Molecular evolutionary genet-
ics  analysis (MEGA) software version 4. 0. Mol  Biol Evol 2007;24(August
(8)):1596–9.
36] Cunha-Neto E, Felgueiras C, Manuel M,  Samri A, Coutinho R, Côrtes F, et al. T cell
crossreactivity of Gag and Nef epitopes derived from Brazilian and European
HIV-1 strains among Brazilian and French HIV-1-infected patients. Aids Res
Hum Retroviruses 2008;24(Suppl. 1). S124–S124.
1 cine 3
[
[
[
[
[
[
[
[
[
[
[
Peptides in a Clade A1- and D-Infected Ugandan Population. AIDS Res Hum
Retroviruses 2012;28(4):384–92.
[48] Brown SA, Slobod KS, Surman S, Zirkel A, Zhan X, Hurwitz JL. Individual HIV112 F.H. Côrtes et al. / Vac
37]  Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA,  et al.
HIV-1-speciﬁc T cell precursors with high proliferative capacity correlate
with low viremia and high CD4 counts in untreated individuals. J Immunol
2008;180(9):5907–15.
38] Coplan PM, Gupta SB, Dubey SA, Pitisuttithum P, Nikas A, Mbewe  B, et al. Cross-
reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades
in  HIV-1-positive individuals from 4 continents. J Infect Dis 2005;191(May
(9)):1427–34.
39] Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, et al. Cross-
clade reactivity of HIV-1-speciﬁc T-cell responses in HIV-1-infected individuals
from Botswana and Cameroon. J Acquir Immune Deﬁc Syndr 2006;42(June
(2)):135–9.
40] Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M,  Pollakis G, et al. Broad
cross-clade T-cell responses to gag in individuals infected with human immu-
nodeﬁciency virus Type 1 non-B clades (A–G): importance of HLA anchor
residue conservation. J Virol 2005;79(September (17)):11247–58.
41] Betts MR,  Krowka J, Santamaria C, Balsamo K, Gao F, Mulundu G, et al. Cross-
clade human immunodeﬁciency virus (HIV)-speciﬁc cytotoxic T-lymphocyte
responses in HIV-infected Zambians. J Virol 1997;71(November (11)):8908–11.
42] Thakar MR,  Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, et al.
Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients
recognize CTL epitopes from a conserved immunodominant region of HIV-1
Gag  and Nef. J Infect Dis 2005;192(September (5)):749–59.1 (2013) 1106– 1112
43] Yu XG, Lichterfeld M,  Perkins B, Kalife E, Mui  S, Chen J, et al. High degree of inter-
clade cross-reactivity of HIV-1-speciﬁc T cell responses at the single peptide
level. AIDS 2005;19(September (14)):1449–56.
44] McKinnon LR, Ball TB, Kimani J, Wachihi C, Matu L, Luo M,  et al. Cross-clade
CD8(+) T-cell responses with a preference for the predominant circulating
clade. J Acquir Immune Deﬁc Syndr 2005;40(November (3)):245–9.
45] Turk G, Gherardi MM,  Laufer N, Saracco M,  Luzzi R, Cox JH, et al. Magnitude,
breadth, and functional proﬁle of T-cell responses during human immu-
nodeﬁciency virus primary infection with B and BF viral variants. J Virol
2008;82(6):2853–66.
46] Bongertz V, Teixeira S, Grinztejn B, Pilotto J, Veloso V, Morgado M, et al. Human
immunodeﬁciency virus type 1 neutralization by plasma from B or F genotype
infected individuals. Mem  Inst Oswaldo Cruz 2005;100(February (1)):85–9.
47] Serwanga J, Mugaba S, Pimego E, Nanteza B, Lyagoba F, Nakubulwa S, et al.
Proﬁle of T Cell Recognition of HIV Type 1 consensus Group M Gag and NefType 1 envelope-speciﬁc T cell responses and epitopes do not segregate by
virus subtype. AIDS Res Hum Retroviruses 2006;22(February (2)):188–94.
